Teva Raises Guidance As Generics Enjoy Solid Growth In Q2

Biosimilars Business Boosted By Adalimumab Launch In US Ahead Of Ustekinumab Opportunity

 
• By Dave Wallace
Teva logo outside building
Teva reported double-digit growth for generics in the second quarter • Source: Shutterstock

More from Earnings

More from Business